The Mayo Clinic Cancer Center (MCCC) considers the Developmental Funds to be one of the most critical components of Cancer Center Support Grant (CCSG) support. Together with institutionally derived MCCC discretionary funds end the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, end the initiation of research projects or generation of pilot data for subsequent peer review grant applications.Given the smell size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the lest funding period, institutionally-derived MCCC discretionary funds end philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, end ell funding for instrumentation end new laboratory set-up costs. Processes are firmly established in the MCCC to solicit end review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities end, in the case of shared resource development, the unambiguous need of investigators with peer reviewed funding. The same level of funding is requested in the next project period to support initiatives in the following categories: ? Continued recruitment of outstanding new research faculty. ? Pilot projects - to eneble the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ? Development of shared resources - to ensure the scientific vitality of MCCC investigators end programs Support of Staff Investigators- MCCC is requesting partial salary support for three Staff Investigators. Neither of these three individuals have e leadership position within the Center, its programs, or its shared resources however, they are judged to be critical by the MCCC leadership to the operation of the Cancer Center for different reasons. The MCCC's Developmental Fund request represents approximately 5.8% of the direct costs requested.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682953
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$299,918
Indirect Cost
$111,446
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7

Showing the most recent 10 out of 340 publications